Company intelligence / Profile preview
Tectonic Therapeutic
Watertown, Massachusetts, United Statestectonictx.com ↗
- Ownership
- Private
- Development stage
- Other
01
Overview
Tectonic’s lead program, TX45, is a Fc-relaxin fusion protein targeting the relaxin receptor for Group 2 pulmonary hypertension. Interim Phase 1b results showed a 17.9% reduction in pulmonary capillary wedge pressure and >30% reduction in pulmonary vascular resistance among patients with more severe disease. The company is advancing to Part B of its Phase 1b trial and has initiated a Phase 2 APEX trial. Another candidate, TX2100, targets HHT and is expected to enter clinical trials by late 2025 or early 2026.
- Therapeutic areas
- CardiovascularRare Diseases
- Modalities
- ProteinMonoclonal antibodyBiologic
- Industry
- Biotech
02
Drug pipeline
12 assets11 more assets in the full pipeline.
Beyond the preview
Go deeper on Tectonic Therapeutic.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Tectonic Therapeutic.